TY  - GEN
AU  - Shimamatsu,Junichiro
AU  - Sasaki,Ken-Ichiro
AU  - Katsuki,Yoshio
AU  - Kawasaki,Tomohiro
AU  - Murasato,Yoshinobu
AU  - Ajisaka,Hidehiko
AU  - Yokoi,Hiroyoshi
AU  - Tashiro,Hideki
AU  - Harada,Atsushi
AU  - Hirakawa,Yuji
AU  - Ishizaki,Yuta
AU  - Ishimatsu,Takashi
AU  - Kagiyama,Kotaro
AU  - Fukumoto,Yoshihiro
AU  - Kakuma,Tatsuyuki
AU  - Ueno,Takafumi
TI  - Prasugrel effectively reduces the platelet reactivity units in patients with genetically metabolic dysfunction of cytochrome P450 2C19 who are treated with long-term dual antiplatelet therapy after undergoing drug-eluting stent implantation
SN  - 1615-2573
PY  - 2020///1026
KW  - Adult
KW  - Aged
KW  - Aged, 80 and over
KW  - Aspirin
KW  - administration & dosage
KW  - Clopidogrel
KW  - Coronary Artery Disease
KW  - blood
KW  - Cytochrome P-450 CYP2C19
KW  - genetics
KW  - Drug Resistance
KW  - Drug Substitution
KW  - adverse effects
KW  - Drug-Eluting Stents
KW  - Dual Anti-Platelet Therapy
KW  - Female
KW  - Humans
KW  - Japan
KW  - Male
KW  - Middle Aged
KW  - Percutaneous Coronary Intervention
KW  - Pharmacogenomic Variants
KW  - Platelet Aggregation
KW  - drug effects
KW  - Platelet Aggregation Inhibitors
KW  - Polymorphism, Single Nucleotide
KW  - Prasugrel Hydrochloride
KW  - Purinergic P2Y Receptor Antagonists
KW  - Risk Factors
KW  - Time Factors
KW  - Treatment Outcome
N1  - Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial
UR  - https://doi.org/10.1007/s00380-019-01499-7
ER  -